Diagnosis for malignant hyperthermia
US5413907A · kind A · utility
5Cited by
1References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 13, 1992 |
| Grant date | May 9, 1995 |
| Priority date | — |
| Expiry date | Apr 13, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A method for isolating a cDNA specific for the human ryanodine receptor is disclosed. The gene is associated with malignant hyperthermia, a hypermetabolic syndrome triggered primarily by inhalation anesthetics. The cDNA can be cloned and expressed in a recombinant plasmid or phage. The cDNA, or fragments thereof, is used as diagnostic probes for individuals at risk for malignant hyperthermia using restriction fragment length polymorphism analysis. The cDNA is that sequenced in FIG. 2 of this specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.